Samantha Craigie
Associate Director, Value & Evidence
Expertise:
Samantha Craigie holds an MSc in Epidemiology and Biostatistics from the University of Western Ontario.
As an Associate Director at EVERSANA in Evidence Synthesis, Samantha has led many global SLR and ITC projects for HTA and regulatory submissions across a variety of disease spaces and indications. Her focus has been on systematic and targeted literature reviews, feasibility assessments for ITCs, contributing to the development and updating of internal best practice guidelines, and mentoring of junior staff.
Samantha Craigie holds an MSc in Epidemiology and Biostatistics from the University of Western Ontario. Prior to joining EVERSANA, Samantha spent nine years working in academic research, with particular focus on systematic reviews, clinical practice guidelines, and research methodology with McMaster University’s Department of Health Research Methodology, Evidence, and Impact. She has co-authored over 30 scientific publications. She has experience in several therapeutic areas, including B-cell lymphomas, chronic pain, thromboprophylaxis for venous thromboembolism, thrombotic microangiopathies, and metastatic castration-resistant prostate cancer. Samantha also holds an Honours BA in Anthropology and a BSc in Life Sciences from McMaster University.
Articles by Samantha Craigie
The Importance of Quality-of-Life Metrics in mCRPC
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable nature of mCRPC, maintaining or improving quality of life (QoL) has become an important goal of therapy for patients, […]
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have been demonstrated for many 1L mCRPC treatments, including novel agents such as talazoparib plus enzalutamide. However, due to the […]